Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.
Kuusanmäki H, Kytölä S, Vänttinen I, Ruokoranta T, Ranta A, Huuhtanen J, Suvela M, Parsons A, Holopainen A, Partanen A, Kuusisto MEL, Koskela S, Räty R, Itälä-Remes M, Västrik I, Dufva O, Siitonen S, Porkka K, Wennerberg K, Heckman CA, Ettala P, Pyörälä M, Rimpiläinen J, Siitonen T, Kontro M. Kuusanmäki H, et al. Among authors: kytola s. Haematologica. 2023 Jul 1;108(7):1768-1781. doi: 10.3324/haematol.2022.281692. Haematologica. 2023. PMID: 36519325 Free PMC article.
Robust scoring of selective drug responses for patient-tailored therapy selection.
Chen Y, He L, Ianevski A, Ayuda-Durán P, Potdar S, Saarela J, Miettinen JJ, Kytölä S, Miettinen S, Manninen M, Heckman CA, Enserink JM, Wennerberg K, Aittokallio T. Chen Y, et al. Among authors: kytola s. Nat Protoc. 2024 Jan;19(1):60-82. doi: 10.1038/s41596-023-00903-x. Epub 2023 Nov 23. Nat Protoc. 2024. PMID: 37996540 Review.
Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial.
Kytölä S, Vänttinen IM, Ruokoranta T, Partanen A, Holopainen A, Saad J, Kuusisto MEL, Koskela S, Räty RK, Itälä-Remes M, Västrik I, Suvela M, Parsons AO, Porkka K, Wennerberg K, Heckman CA, Jalkanen T, Huttunen T, Ettala P MD, Rimpiläinen J, Siitonen T, Pyörälä M, Kuusanmäki H, Kontro M. Kytölä S, et al. Blood. 2024 Oct 2:blood.2024024968. doi: 10.1182/blood.2024024968. Online ahead of print. Blood. 2024. PMID: 39357056
NGS of brush cytology samples improves the detection of high-grade dysplasia and cholangiocarcinoma in patients with primary sclerosing cholangitis: A retrospective and prospective study.
Boyd S, Mustamäki T, Sjöblom N, Nordin A, Tenca A, Jokelainen K, Rantapero T, Liuksiala T, Lahtinen L, Kuopio T, Kytölä S, Mäkisalo H, Färkkilä M, Arola J. Boyd S, et al. Among authors: kytola s. Hepatol Commun. 2024 Mar 29;8(4):e0415. doi: 10.1097/HC9.0000000000000415. eCollection 2024 Apr 1. Hepatol Commun. 2024. PMID: 38551383 Free PMC article.
Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study).
Aho S, Osterlund E, Ristimäki A, Nieminen L, Sundström J, Mäkinen MJ, Kuopio T, Kytölä S, Ålgars A, Ristamäki R, Heervä E, Kallio R, Halonen P, Soveri LM, Nordin A, Uutela A, Salminen T, Stedt H, Lamminmäki A, Muhonen T, Kononen J, Glimelius B, Isoniemi H, Lehto JT, Lehtomäki K, Osterlund P. Aho S, et al. Among authors: kytola s. Cancers (Basel). 2024 Mar 5;16(5):1052. doi: 10.3390/cancers16051052. Cancers (Basel). 2024. PMID: 38473410 Free PMC article.
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
Tobiasson M, Pandzic T, Illman J, Nilsson L, Weström S, Ejerblad E, Olesen G, Björklund A, Olsnes Kittang A, Werlenius O, Lorentz F, Rasmussen B, Cammenga J, Weber D, Lindholm C, Wiggh J, Dimitriou M, Moen AE, Yip Lundström L, von Bahr L, Baltzer-Sollander K, Jädersten M, Kytölä S, Walldin G, Ljungman P, Groenbaek K, Mielke S, Jacobsen SEW, Ebeling F, Cavelier L, Smidstrup Friis L, Dybedal I, Hellström-Lindberg E. Tobiasson M, et al. Among authors: kytola s. J Clin Oncol. 2024 Apr 20;42(12):1378-1390. doi: 10.1200/JCO.23.01159. Epub 2024 Jan 17. J Clin Oncol. 2024. PMID: 38232336
Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts.
Osterlund E, Ristimäki A, Mäkinen MJ, Kytölä S, Kononen J, Pfeiffer P, Soveri LM, Keinänen M, Sorbye H, Nunes L, Salminen T, Nieminen L, Uutela A, Halonen P, Ålgars A, Sundström J, Kallio R, Ristamäki R, Lamminmäki A, Stedt H, Heervä E, Kuopio T, Sjöblom T, Isoniemi H, Glimelius B, Osterlund P. Osterlund E, et al. Among authors: kytola s. Int J Cancer. 2024 Feb 1;154(3):488-503. doi: 10.1002/ijc.34733. Epub 2023 Sep 19. Int J Cancer. 2024. PMID: 37724848
N-Glycomic Profiling of Microsatellite Unstable Colorectal Cancer.
Ukkola I, Nummela P, Heiskanen A, Holm M, Zafar S, Kero M, Haglund C, Satomaa T, Kytölä S, Ristimäki A. Ukkola I, et al. Among authors: kytola s. Cancers (Basel). 2023 Jul 11;15(14):3571. doi: 10.3390/cancers15143571. Cancers (Basel). 2023. PMID: 37509233 Free PMC article.
Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study.
Uutela A, Nordin A, Osterlund E, Halonen P, Kallio R, Soveri LM, Salminen T, Ålgars A, Ristimäki A, Ovissi A, Lamminmäki A, Muhonen T, Kononen J, Ristamäki R, Heervä E, Stedt H, Lehtomäki K, Kytölä S, Sundström J, Mäkinen MJ, Nieminen L, Kuopio T, Keinänen M, Osterlund P, Isoniemi H; RAXO Study Group. Uutela A, et al. Among authors: kytola s. Br J Surg. 2023 Jul 17;110(8):931-935. doi: 10.1093/bjs/znac424. Br J Surg. 2023. PMID: 36511370 Free PMC article. No abstract available.
81 results